Literature DB >> 31292607

Risk factors for chylothorax and persistent serous effusions after congenital heart surgery.

Anna Raatz1, Martin Schöber1, Robert Zant1, Robert Cesnjevar2, André Rüffer3, Ariawan Purbojo2, Sven Dittrich1, Muhannad Alkassar1.   

Abstract

OBJECTIVES: This study evaluated the various risk factors for chylothorax and persistent serous effusions (>7 days) after congenital heart surgery and developed equations to calculate the probability of their occurrence.
METHODS: We performed a retrospective review of different medical databases at the University Hospital of Erlangen between January 2014 and December 2016. Full model regression analysis was used to identify risk factors, and prediction algorithms were set up to calculate probabilities. Discriminative power of the models was checked with the help of C-statistics.
RESULTS: Of 745 operations on 667 patients, 68 chylothoraxes (9.1%) and 125 persistent pleural effusions (16.8%) were diagnosed. Lowest temperature [P = 0.043; odds ratio (OR) 0.899], trisomy 21 (P = 0.001; OR 5.548), a higher vasoactive inotropic score on the day of surgery (P = 0.001; OR 1.070) and use of an assist device (P = 0.001; OR 5.779) were significantly associated with chylothorax. Risk factors for persistent serous effusions were a given or possible involvement of the aortic arch during the operation (P = 0.000; OR 3.982 and 2.905), univentricular hearts (P = 0.019; OR 2.644), a higher number of previous heart operations (P = 0.014; OR 1.436), a higher vasoactive inotropic score 72 h after surgery (P = 0.019; OR 1.091), a higher central venous pressure directly after surgery (P = 0.046; OR 1.076) and an aortic cross-clamp time >86 min (P = 0.023; OR 2.223), as well as use of an assist device (P = 0.002; OR 10.281). The prediction models for both types of effusions proved to have excellent discriminative power.
CONCLUSIONS: Persistent serous effusion is associated with a higher vasoactive inotropic score 72 h after surgery, an aortic cross-clamp time >86 min and elevated central venous pressure directly after surgery, which, in combination, potentially indicate cardiac stress. The developed logistic algorithm helps to estimate future likelihood.
© The Author(s) 2019. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Cardiac insufficiency; Cardiac surgery; Chylothorax; Congenital heart disease; Persistent effusions; Risk factor

Year:  2019        PMID: 31292607     DOI: 10.1093/ejcts/ezz203

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  5 in total

1.  Medical Interventions for Chylothorax and their Impacts on Need for Surgical Intervention and Admission Characteristics: A Multicenter, Retrospective Insight.

Authors:  Rohit S Loomba; Joshua Wong; Megan Davis; Sarah Kane; Brian Heenan; Juan S Farias; Enrique G Villarreal; Saul Flores
Journal:  Pediatr Cardiol       Date:  2021-01-04       Impact factor: 1.655

Review 2.  Diagnosis and Management of Lymphatic Disorders in Congenital Heart Disease.

Authors:  Benjamin Kelly; Sheyanth Mohanakumar; Vibeke Elisabeth Hjortdal
Journal:  Curr Cardiol Rep       Date:  2020-10-10       Impact factor: 2.931

3.  Clone Selection Artificial Intelligence Algorithm-Based Positron Emission Tomography-Computed Tomography Image Information Data Analysis for the Qualitative Diagnosis of Serous Cavity Effusion in Patients with Malignant Tumors.

Authors:  Jing Wei; Pingwei Li; Huai Zhang; Ronghua Zhu
Journal:  J Healthc Eng       Date:  2021-12-18       Impact factor: 2.682

4.  Predictive factors contributing to prolonged recovery in patients after Fontan operation.

Authors:  Yixiao Song; Liping Wang; Mingjie Zhang; Xi Chen; Yachang Pang; Jiaqi Liu; Zhuoming Xu
Journal:  BMC Pediatr       Date:  2022-08-24       Impact factor: 2.567

5.  Neutrophil-to-lymphocyte ratio is prognostic factor of prolonged pleural effusion after pediatric cardiac surgery.

Authors:  Kazuki Yakuwa; Kagami Miyaji; Tadashi Kitamura; Takashi Miyamoto; Minoru Ono; Yukihiro Kaneko
Journal:  JRSM Cardiovasc Dis       Date:  2021-04-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.